UNSPSC 51271618: Ropivacaine

This classification denotes an immunosuppressant with the molecular formula C17H26N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7IO5LYA57N, chemically known as n-(2,6-dimethylphenyl)-1-propyl-piperidine-2-carboxamide but generally known as ropivacaine, which bears US NIH Compound Identifier 71273. European Medicines Agency schedules Ropivacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10382MIG.

UNSPSC 51271618 Ropivacaine is a Commodity code covering a specific local anesthetic pharmaceutical product that state and local government procurement offices source primarily through cooperative purchasing frameworks rather than direct individual solicitations. Recent activity shows that ropivacaine, along with other generic multi-source pharmaceuticals and OTC products, is being procured through multistate cooperative agreements managed by established purchasing alliances. The goods being bought under this code are pharmaceutical products with specific National Drug Codes (NDCs) for use across state and local government health facilities, correctional systems, and emergency services; vendors must comply with current Good Manufacturing Practices (cGMP), FDA requirements, and the Drug Supply Chain Security Act (DSCSA), and all products must maintain minimum shelf-life standards and be sourced through authorized pharmaceutical wholesalers with established chargeback systems.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 to establish multiple contracts for generic pharmaceuticals and OTC products with a response deadline of March 26, 2026. The MMCAP contract spans participating state and local government facilities across Minnesota and Oregon, with awarded vendors required to supply products through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, and to maintain insurance including $5,000,000 commercial general liability per occurrence. Evaluation criteria weight price competitiveness at 75 percent, with the remaining 25 percent split among fixed pricing, administrative fee compliance, EDI capability, and flexibility on pricing structures (flat price, net price formats, or WAC-minus). The contract term is two years for new vendors with optional MMCAP extensions, and incumbent vendors' agreements extend through June 30, 2028. Specific award values are not disclosed, but vendors pay a 3 percent administrative fee on all purchases and face performance penalties ranging from $200 to $1,500 per violation.